Core Viewpoint - The Ministry of Agriculture and Rural Affairs has approved the new veterinary drug registration for a four-in-one inactivated vaccine developed by Pulaike Bioengineering Co., Ltd. and its subsidiary Huizhong Bio, which targets multiple poultry diseases [1] Group 1: Product Development - The four-in-one inactivated vaccine addresses Newcastle disease, infectious bronchitis, avian influenza (H9 subtype), and avian adenovirus disease (Group I, Type 4) [1] - The total investment in the product development amounts to 7.3635 million yuan [1] - The vaccine provides immunity for at least six months with a single injection [1] Group 2: Market Position - Currently, there are no similar four-in-one inactivated vaccines for poultry available in the market [1] - The acquisition of the new veterinary drug registration certificate is expected to enhance the company's product competitiveness [1] - This development is anticipated to create a new growth point for the company's performance [1]